Unlock instant, AI-driven research and patent intelligence for your innovation.
Wedelolactone pharmaceutical use
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of wedelolide and its use, which is applied in the field of pharmaceutical use of wedelolide, and can solve the problems that there are no reports of drugs for angiogenesis, intimal hyperplasia, etc.
Inactive Publication Date: 2016-04-20
XIAMEN UNIV
View PDF3 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, the use of wedelolide in the preparation of drugs for inhibiting angiogenesis and intimal hyperplasia has not been reported yet.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0033] The rat model of neointimal hyperplasia and atherosclerosis caused by balloon injury was used to observe the effect of wedelolide on the neointimal hyperplasia of the common carotid artery on the injured side of the model rats.
[0034] The specific method steps of the experiment are as follows:
[0035] 1) Experimental animals and reagents
[0036] 40 rats, male, with an average weight of 240-260 g, were purchased from the Experimental Animal Center of Xiamen University.
[0037] Wedelide was purchased from Shanghai Yuanye Biotechnology Co., Ltd.
[0038] 2) Animal handling methods
[0039] Rat feeding environment: temperature 23±1°C, humidity: 40%-60%, natural light, free drinking water, free eating. After 1 week of adaptation, they were randomly divided into 5 groups with 8 rats in each group, which were respectively record...
Embodiment 2
[0056] Example 2 Wedelolide inhibits the proliferation and migration of vascular smooth muscle cells (VSMC) cultured in vitro
[0057] The primary cultured rat thoracic aortic vascular smooth muscle cells were stimulated with platelet-derived growth factor (PDGF) to proliferate and migrate, and the inhibitory effect of wedelolide on PDGF-induced vascular smooth musclecell proliferation and migration was observed.
[0058] The specific method steps of the experiment are as follows:
[0060] Rats, male, 130-150 g, were purchased from the Experimental Animal Center of Xiamen University.
[0061] After chloralhydrate anesthetizes the rat, make a median chest incision, separate the thoracic aorta, wash it in PBS, cut it into small pieces, and paste it on a petri dish. After it is firmly attached, add DMEM medium containing 20% FBS for culture , change the medium for about 3 days, and subculture after a certain number of cells climb out. Pass...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The present invention discloses wedelolactone pharmaceutical use, especially wedelolactone pharmaceutical use in manufacture of drugs to inhibit vascular neointimal hyperplasia and resist atherosclerosis, wedelolactone has the effect to inhibit the vascular neointimal hyperplasia, and the effect to inhibit the vascular neointimal hyperplasia is achieved mainly through the inhibition of proliferation and migration of vascular smooth muscle cells. The wedelolactone pharmaceutical use provides a research idea for use of the wedelolactone in manufacture of the drugs to inhibit the vascular neointimal hyperplasia and resist the atherosclerosis, and is expected to be applied to coronary angioplasty, stent implantation and other operation and prevention and treatment of the vascular neointimal hyperplasia and resist the atherosclerosis caused by improper diets and other reasons.
Description
technical field [0001] The invention relates to the pharmaceutical application of wedelolide, especially the application in the preparation of drugs for inhibiting angiogenesis and intimal hyperplasia and anti-atherosclerosis drugs. Background technique [0002] Coronary arterybypass grafting, heart stent and other operations are widely used in the world because they can effectively relieve symptoms such as angina pectoris and myocardial infarction in patients with coronary atherosclerotic heart disease and prolong life. Injury, vascular smooth musclecell (vascular smooth musclecell, VSMC) proliferation and migration and accumulation of extracellular matrix lead to angiogenesis, intimal hyperplasia, and subsequent atherosclerosis. The vascular stenosis caused by this process seriously affects the long-term efficacy. The abnormal proliferation and migration of VSMC is the main cause of vascular disease, which directly leads to the occurrence of neovascular neointimal hyper...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More